drugset / Trial / NCT05666960
R-3750 in Patients With Mild to Moderate Ulcerative Colitis
Phase 1
Recruiting
36 enrolled
Rise Therapeutics LLC
Mayo Clinic · collabUniversity of Colorado, Denver · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this study is to determine the safety and tolerability of orally taken probiotic (R-3750) in patients with mild to moderate ulcerative colitis. Patients will take an oral dosage of probiotic (R-3750) and provide patient-reported and physician scored measures of their colitis. Blood and fecal evaluations of inflammation and assessment of probiotic (R-3750) on fecal levels will also be measured.
Timeline
- Start
- 2023-02-27
- Primary completion
- 2026-07
- Completion
- 2026-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | R-3750 | Other / unclassified | — | Oral |